Introduction
Chronic kidney disease (CKD) is a worldwide public health problem, affecting approximately 11% of the US adult population [1] . The prevalence of renal failure, a major outcome of CKD, is projected to double by the end of this decade [2] . Blood pressure reduction remains an important goal in preventing or delaying the progression of CKD into renal failure and reducing the risk of cardiovascular disease. Even though the current awareness, treatment, and rate of blood pressure control [systolic blood pressure (SBP) 5140 mmHg and diastolic blood pressure (DBP) 590 mmHg] have slightly improved, 30% of hypertensive individuals remain undiagnosed, and blood pressure control is achieved in only 34% of those treated [3 . . ]. The level of arterial blood pressure has a graded and independent relationship with cardiovascular disease, in that above an SBP of 115 mmHg or DBP of 75 mmHg the risk of cardiovascular events doubles for each incremental increase of 20 mmHg in SBP or 10 mmHg in DBP [4] . The recent Joint National Committee (JNC 7) report, in agreement with the American Diabetes Association, Canadian Hypertension Society, and National Kidney Foundation, thus recommends a more aggressive lowering of blood pressure below 130/80 mmHg in high-risk patients, those with diabetes or renal insufficiency [3 . . ,5,6].
CKD is defined as kidney damage, as confirmed by kidney biopsy or markers of damage (4300 mg/day albuminuria or 200 mg albumin/g creatinine, abnormalities of urine dipstick or sedimentation examination, or abnormalities of imaging studies) or glomerular filtration rate (GFR) less than 60 ml/min per 1.73 m 2 for 3 months or longer [1] . In addition to dietary and other therapeutic life-style modifications, pharmacological therapy with antihypertensive agents is necessary in CKD to achieve the blood pressure goal in patients with blood pressure higher than 130/80 mmHg [3 . . ]. The reasons for the inadequate control of blood pressure are many. They include: (1) failure to select the proper class of antihypertensive medication for certain patient groups;
(2) failure to administer the proper dose of medication and poor patient compliance with the prescribed regimen; and (3) the coexistence of aggravating factors such as obesity, physical inactivity, excessive salt intake and others. Many hypertensive patients, especially those with certain diseases such as diabetes or renal insufficiency require two or more antihypertensive medications to lower their blood pressure adequately to the recommended goals [7] . The use of fixed-dose combination antihypertensive agents provides several advantages, such as improved compliance, decreased costs, and further blood pressure reductions [7] . The recent literature had reported numerous studies that assess the efficacy and tolerability of fixed-dose combination therapy in hypertensive patients [8] [9] [10] [11] [12] [13] . A meta-analysis of 50 placebo-controlled trials involving fixed-dose combination antihypertensive agents [14] indicated that the efficacy of drugs in combination was additive, but the prevalence of adverse effects was less than additive.
Calcium antagonists (CAs) are among the most widely used class of antihypertensive medications. The impact of this heterogeneous class of medications is not altogether consistent. This article focuses on the advantages and disadvantages of the two classes of CAs as part of the antihypertensive regimen in CKD. Emphasis is placed on the impact of CAs in improving renal outcomes and preventing or delaying the progression to end-stage renal disease (ESRD). These data are discussed in the context of long-term clinical studies (defined as a follow-up period of more than 2 years) in both diabetic and non-diabetic renal disease, in the presence and absence of other antihypertensive drug classes.
Before considering the data in both animal models and clinical outcome trials with these agents, a few points need to be made clear regarding the timing of disease intervention. Unlike studies in animal models, in which antihypertensive intervention commonly occurs early in the disease course, studies in human disease intervene later in the natural history, generally when at least 35-50% of renal function is lost. The outcomes from various clinical studies may thus not be consistent. This relates to the observation that the greatest impact on slowing renal disease progression in any given trial is observed for those serum creatinine values greater than 1.5 mg/dl or proteinuria in excess of 1 g [15] [16] [17] . Comparing the results of a trial with a mean baseline GFR of 90 ml/min with one of 50 ml/min both of similar duration, would thus yield different results in terms of renal function decline rates. For example, large differences in renal function decline rates are observed when comparing the Appropriate Blood Pressure in Diabetes (ABCD) study with the Irbesartan in Diabetic Nephropathy Trial (IDNT) results (see below) [16, 18] .
Another variable to consider in the outcome trials of renal disease progression is the achieved level of blood pressure, not the randomization goal. It is clear from a retrospective analysis of cardiovascular and renal trials in individuals with diabetes that as little as a 4 or 5 mm difference in diastolic pressure between the groups yields a tremendous difference in outcome [19] [20] [21] . It is therefore difficult to make direct comparisons when comparing studies unless these factors are taken into account.
Calcium antagonists in diabetic renal disease
CAs have been found to have variable effects on the progression of diabetic nephropathy. Studies in animal models of diabetic nephropathy have uniformly demonstrated a failure to reduce intraglomerular pressure or prevent the development of either glomerulosclerosis or albuminuria with dihydropyridine calcium antagonists (DHPCAs) available in north America [22,23,24 . . ,25] . Moreover, in most clinical studies of individuals with nephropathy attributed to diabetes, those given this subclass of agents failed to demonstrate a reduction in macroalbuminuria, whereas they do manifest reductions in microalbuminuria [26] [27] [28] . Conversely, in animal models of type 1 diabetes, the non-DHPCAs verapamil and diltiazem, like the angiotensin-converting enzyme (ACE) inhibitors, reduce mesangial matrix expansion, decrease proteinuria and partly reduce intraglomerular pressure [29] [30] [31] [32] . Animal studies in diabetic beagle dogs demonstrated a slowing of matrix expansion with either lisinopril or diltiazem [29] . Reviews of animal studies with CAs that have evaluated the development of glomerulosclerosis confirmed this observation and showed similar results for verapamil [7,24 . . ].
Studies in individuals with type 2 diabetes that examine the effects of non-DHPCAs on renal disease progression generally demonstrated a positive effect on outcome. This statement is supported by a study of 52 patients with diabetic nephropathy, whose mean GFR was 63 ml/ min. These participants had their hypertension treated with an ACE inhibitor (lisinopril), non-DHPCAs (verapamil or diltiazem SR) or a beta-blocker (atenolol). They were followed for 6 years [33] . The primary endpoint of the study was a change in the creatinine clearance slope. Renal function in the beta-blocker group declined at a rate of 3.4 ml/min per year compared with the other groups whose average decline was 1.6 ml/min per year; the normal rate of GFR loss is approximately 1 ml/min per year. Proteinuria was reduced to a similar extent in the lisinopril and the non-DHPCA groups, an effect independent of blood pressure control. A lesser degree of proteinuria reduction was seen in the atenolol group. One factor that may have contributed to the difference among these groups is that the systolic blood pressure in the beta-blocker group was significantly higher by 4 mmHg compared with either of the other groups, but was less than 140 mmHg. Nevertheless, these findings were supported by a 5-year randomized study of African-American participants with diabetic nephropathy. In this single-centre randomized trial, verapamil slowed the progression of renal disease to 1.8 ml/min per year compared with atenolol at 3.8 ml/ min per year, given similar reductions in arterial pressure [34] . Unlike the previous study, however, no significant difference in blood pressure control was noted between the groups. Therefore, whereas blood pressure control to a range of between 135-140/85-90 mmHg was associated with the slow progression of renal disease, regardless of the agent used, the non-DHPCAs may have a relatively greater effect that may be related to reductions in proteinuria, as suggested by recent consensus reports and recently observed in the CO-OPERATE study [12, 35, 36] .
Conversely, investigations into renal disease progression with DHPCAs in individuals with and without type 2 diabetes have failed to show any significant reduction in albuminuria or slowing of the progression of nephropathy [37, 38] . IDNT compared a DHPCA (amlodipine) with a control group treated with placebo and other agents, primarily diuretics and beta-blockers, in type 2 diabetic nephropathy. A decline in GFR and the onset of kidney failure was similar in both groups, but the amlodipine group had higher levels of proteinuria [16] . When compared with irbesartan, the amlodipine group had a 37% higher risk of doubling in serum creatinine, a 27% less reduction in proteinuria, and a 23% higher risk of the combined primary endpoint of doubling of serum creatinine, ESRD, or death after a median follow-up of 2.6 years, despite a similar degree of blood pressure reduction (achieved blood pressure of 140/77 mmHg) [16] .
The ABCD study evaluated the effects of moderate (achieved blood pressure of 138/86 mmHg) versus intensive (achieved blood pressure of 132/78 mmHg) blood pressure reduction as well as DHPCA (nisoldipine) versus ACE inhibitor (enalapril) in normotensive and hypertensive type 2 diabetic patients. After 5 years of follow-up, there was no difference between the two levels of blood pressure control or DHPCA versus ACE inhibitor with regard to a change in creatinine clearance or a reduction in albuminuria in the hypertensive cohorts [18] . There was, however, a lower incidence of overall mortality in the intensive group [39] . Given the near-normal renal function in the subjects at study entry, only 20% of patients advanced from normoalbuminuria to microalbuminuria (30-300 mg/day) and from microalbuminuria to overt albuminuria (4300 mg/day) over the 5year follow-up period. A demonstration of a difference in renal outcome in this subset of patients may have been blunted by the low level of achieved blood pressure in both groups, or may require a longer follow-up period. In the normotensive cohorts, intensive treatment (128/ 75 mmHg) slowed the progression from normoalbuminuria to microalbuminuria and from microalbuminuria to albuminuria given a 9 mmHg difference in achieved SBP among the groups [39] . There was, however, no difference between the DHPCA and ACE inhibitor group. Unlike IDNT, ABCD failed to demonstrate a significant difference in proteinuria reduction or GFR decline between DHPCAs and blockers of the reninangiotensin system (RAS), partly because of the more advanced degree of renal insufficiency in IDNT participants.
Although DHPCAs alone failed to reduce proteinuria or alter renal outcomes beyond their blood pressurelowering effects, the combination with an ACE inhibitor or angiotensin II receptor blocker (ARB) provided further blood pressure reduction without affecting the renoprotective properties of the RAS blockers. In the Reduction of Endpoints in Non-insulin-dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan study, subjects were randomly assigned to receive losartan versus placebo in addition to other antihypertensive medications [40 . ]. Fifty-four per cent of the participants receiving a DHPCA at study entry and those administered placebo and subsequently receiving DHPCAs during the trial had a significantly higher risk of reaching the primary composite endpoint (doubling of serum creatinine, ESRD, or death) compared with those who did not receive DHPCAs. This finding may be attributed to more advanced renal disease or more resistant hypertension. In contrast, patients taking a DHPCA at baseline or during the study who were randomly assigned to receive losartan showed a slower progression to ESRD than the entire losartan arm.
Finally, four different systematic reviews or metaanalyses of clinical studies of both type 1 and type 2 diabetes confirmed the observation of a relatively greater impact on slowing the progression of renal disease with non-DHPCAs compared with DHPCAs [41] [42] [43] [44] . ARBs are more effective than other antihypertensive classes in slowing the progression of kidney disease in type 2 diabetes with macroalbuminuria and decreased GFR [15, 16] . Table 1 summarizes the long-term (defined as follow-up period of more than 2 years) clinical trials of CAs in both diabetic and non-diabetic patients.
Disparate effects of dihydropyridine and non-DHPCAs on morphological changes in the kidney and renal disease progression in diabetes may be accounted for by differences in the following factors: (1) glomerular membrane permeability [28] ; (2) type and degree of calcium channel inhibition [45] ; (3) transcapillary pressure reductions [30, 46] ; and (4) renal autoregulatory processes [31, 32] . A study of the animal model of renal insufficiency clearly documented the loss of renal autoregulation in the presence of a DHPCA, but to a much lesser degree with non-DHPCA [32] . The intrarenal effects of the different subclasses of CAs in the diabetic kidney are shown in Table 2 .
Calcium antagonists in non-diabetic renal disease
Non-diabetic renal disease encompasses a wide array of diseases grouped together in epidemiological and clinical trials. ACE inhibitors have been shown to be more effective in slowing the progression of most non-diabetic CKD, with greater beneficial effect in higher levels of proteinuria as seen in glomerular diseases [47 . ,48] .
The Systolic Hypertension in Europe trial compared the DHPCA, nitrendipine, with true placebo in older hypertensive patients, which resulted in a reduction in the risk of proteinuria and mild renal dysfunction as well as a significant decrease in serum creatinine in previously microalbuminuric patients [49] . This benefit is probably related to the 11.6/4.1 mmHg blood pressure difference between the active and placebo groups. Conversely, data from the largest and longest term study of renal disease progression, the African American Study of Kidney Disease, in which 1094 participants with hypertensive nephrosclerosis (GFR 20-65 ml/min per 1.73 m 2 ) were randomly assigned to receive ramipril, metoprolol, or amlodipine, found no difference in the primary outcome of the rate of change in GFR slope in the entire cohort [47 . ]. However, the ACE inhibitor was more efficacious in the secondary clinical composite outcome of a 50% reduction in GFR, ESRD, or death. Larger effects were observed in patients with greater levels of proteinuria and lower GFR. Both ACE inhibitors and beta-blocker groups reduced the risk of kidney failure and combined kidney failure and death when compared with the DHPCA group. Importantly, 74% of patients in the ACE inhibitor group received furosemide as part of the antihypertensive combination to reduce blood pressure to goal, suggesting that diuretics are needed with ACE inhibitors to achieve the blood pressure goal and show benefit in advanced renal disease. In the large sub-group of non-diabetic CKD (GFR560 ml/min per 1.73 m 2 ) in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, no additional beneficial effect of ACE inhibitors could be demonstrated compared with chlorthalidone on the decline in estimated Table 1 . Summary of long-term (more than 2 years) completed studies with calcium antagonists in patients with either diabetic or non-diabetic chronic kidney disease GFR or the onset of kidney failure over 4 years. This finding may have been partly caused by the absence of a diuretic/ACE inhibitor combination and small persistent differences in blood pressure compared with the other groups [50] .
The beneficial effect of DHPCAs in combination with ACE inhibitors is evident in the prospective evaluation of non-diabetic patients with chronic, proteinuric nephropathies enrolled in the Ramipril Efficacy in Nephropathy study. Sixty-three per cent of the participants randomly assigned to ramipril or conventional therapy were treated with DHPCAs. Overall, the CA-treated group had higher proteinuria and a faster decline in the GFR rate compared with the non-CA-treated group [51] .
The difference was significant in the placebo group but not when used with the ACE inhibitor. There was also higher proteinuria in the CA-treated patients for a mean arterial pressure greater than 100 mmHg, but no significant difference in mean arterial pressure of 100 mmHg or less. Therefore, the adverse effect of DHPCAs on non-diabetic CKD can be blunted by combination with ACE inhibitors or further blood pressure reduction. Similar results were reported in the NEPHROS study. The combination of an ACE inhibitor and a DHPCA in 51 non-diabetic patients with renal disease slowed the loss of GFR compared with 53 patients on DHPCAs alone, but no difference with the ACE inhibitor group [11] . The DHPCA (felodipine) group had an increase in albuminuria as well as serum creatinine after 2 years of follow-up. [23] . That is, if a DHPCA is given with an ACE inhibitor increases in proteinuria seen with the DHPCA alone do not occur. This is what was observed in the VVANNTT study with the combination of amlodipine with trandolapril [52] . However, blood pressure was significantly lower in the amlodipine group compared with verapamil, and the change in proteinuria, when corrected for the pressure difference, favored verapamil, albeit not significantly. Given the variability of proteinuria, that study was markedly underpowered and therefore has limitations.
All individuals with CKD have a high risk of cardiovascular events as a result of both the traditional risk factors of diabetes, hypertension, and hyperlipidemia, as well as CKD-related risk factors of coronary calcification and proteinuria. An alteration in the natural history of cardiovascular events and renal disease progression is seen in clinical trials when blood pressure reduction occurs with non-DHPCAs [53] . DHPCAs in the absence of ACE inhibitors or ARBs tend not to alter renal disease progression as well as blockers of the renin-angiotensinaldosterone system and may increase the risk of the development of heart failure [16,40 . ,50] .
Taken together, these observations indicated that, in patients with either diabetic or non-diabetic kidney disease, lower levels of blood pressure (5130/ 80 mmHg) can help delay and may prevent the progression to ESRD or death. The available data as well as the current recommendations of the Joint National Committee Report on the Diagnosis, Prevention and Treatment of Hypertension, JNC 7, mandated that an ACE inhibitor or an ARB be included in the 'antihypertensive cocktail' of medications used to lower blood pressure in patients with either diabetic nephropathy or non-diabetic renal insufficiency with proteinuria. The advantage of renin-angiotensin blockers is more pronounced in more advanced stages of CKD marked by lower GFR levels and a higher degree of proteinuria. Moreover, DHPCAs should not be utilized without the concomitant use of an ACE inhibitor/ARB in individuals with advanced levels of kidney disease (stages 3-5), because alone they do not reduce cardiovascular events or slow the progression of renal disease beyond their blood pressure-lowering effect. Their use in the absence of an ARB or an ACE inhibitor in stages 1 and 2 nephropathy is more controversial because the data are scant and are generally derived from small studies. Conversely, in two large trials, CONVINCE and the soon to be published INVEST, of more than 38 000 individuals, non-DHPCAs have been shown to reduce cardiovascular events, the most common cause of death among patients with kidney disease, as well as to reduce proteinuria to a greater extent than DHPCAs [53, 54] . On the basis of changes in proteinuria, this benefit on renal disease progression may be accentuated when non-DHPCAs are used in concert with the blockers of the RAS, although outcome trials are needed to confirm this assertion.
